---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-041236"
form_type: "8-K"
ticker: "ASRT"
cik: "0001808665"
company_name: "Assertio Holdings, Inc."
filed_at: "2026-04-09T23:59:59+00:00"
generated_at: "2026-05-15T06:48:43.433646+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Assertio to be acquired by Garda for $18/share plus CVR; sells assets to Cosette for $35M

## Summary
- Garda Therapeutics to acquire Assertio via cash tender offer at $18.00 per share plus one CVR per share.
- Concurrently, Assertio sells its INDOCIN, SPRIX, and other product franchises to Cosette for $35M cash plus up to $35M in milestones.
- Equity investors commit $17M and Colbeck provides $87M debt financing; no financing condition for the offer.
- Closing conditions include minimum net cash of $115M; termination fee is $4.8M ($1.75M for qualified bidder).
- Company to launch note offer for its $40M 6.50% Convertible Notes due 2027 contingent on merger.

## SEC filing metadata
- accession: 0001104659-26-041236
- form_type: 8-K
- ticker: ASRT
- cik: 0001808665
- company_name: Assertio Holdings, Inc.
- filed_at: 2026-04-09T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1808665/000110465926041236/0001104659-26-041236-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1808665/000110465926041236/tm2611405d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-041236
- JSON: https://secwatch.observer/filing/0001104659-26-041236.json
- Plain text: https://secwatch.observer/filing/0001104659-26-041236.txt

## Source-grounded claims
- claim_id: bd154e5d0f416e9b19c5648be6983ab6dd39925e
  claim: Assertio Holdings, Inc. entered into Merger Agreement with Garda Therapeutics, Inc. (Parent) and Audi Merger Sub, Inc. (Purchaser) (effective 2026-04-08).
  evidence_excerpt: On April 8, 2026, Assertio Holdings, Inc. (the " Company " or " Assertio ") entered into an Agreement and Plan of Merger (the " Merger Agreement ") with Garda Therapeutics, Inc., a Delaware corporation (" Parent "), and Audi Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (" Purchaser ").
  evidence_url: https://www.sec.gov/Archives/edgar/data/1808665/000110465926041236/0001104659-26-041236-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.